BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc.（BBIO）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
bbio · 股价预测 · 26 位分析师（近3月）· FMP · 更新于 2026年6月8日
分析师评级与共识
基于过去 3 个月内 26 位华尔街分析师
Buy
26 位分析师
共识
评级分布
12 个月目标价
High
$157
Consensus
$105
+55.6% upside
Low
$83.00
Median: $100 · Last Close: $67.61
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$105.21
55.6% upside
High Target
$157
132.2%
Low Target
$83
22.8%
Current Price
$67.61
as of today
Based on analyst price targets, the BBIO stock price prediction for the next 12 months ranges from $83 to $157. The consensus BBIO price forecast of $105.21 implies 55.6% upside from the current price of $67.61.
短期股价预测
算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $66.83 | ↓ 1.16% |
1-day model range: $66.51–$67.15. Peak: $67.15 (-1.16%).
长期股价预测
年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $89 | +32.1% |
| 2028 | $108 | +59.6% |
| 2029 | $123 | +81.3% |
| 2030 | $133 | +97.3% |
| 2031 | — | +108.6% |
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · BBIO · Jun 8, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-28 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-05-28 | Morgan Stanley | Maintains | Overweight→Overweight |
| 2026-05-26 | Raymond James | Downgrade ↓ | Outperform→Market Perform |
| 2026-05-11 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-05-08 | Evercore ISI Group | Maintains | Outperform→Outperform |
| 2026-04-29 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-04-29 | Truist Securities | Maintains | Buy→Buy |
| 2026-04-28 | Mizuho | Maintains | Outperform→Outperform |
| 2026-04-27 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-03-18 | Mizuho | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on BridgeBio Pharma, Inc. (BBIO) stock. Of the recent 147 rating actions, 2 were upgrades and 2 were downgrades. 26 analysts currently cover BBIO.
分析师推荐趋势
BBIO analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 4 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$965M
↓ 60.5% YoY
Revenue Next Year
$1.6B
↑ 66.7% YoY
EPS This Year
$-2.18
EPS Next Year
$0.59
↓ 127.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast BBIO EPS of $-2.18 for the current fiscal year, based on estimates from 13 analysts. The BBIO revenue forecast is $965M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
BBIO 股价预测由两类独立数据源支撑：来自 26 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。BBIO 的共识目标价为 $105.21（+55.6% 上行空间），分析师共识为 Buy。
BBIO 的短期预测（明日）为 $66.83（-1.16%）。 BBIO 对 2027 年的股价预测均值为 $89。 BBIO 对 2030 年的预测区间为 $126–$140。
BridgeBio Pharma, Inc. 在 NASDAQ 上市，代码 BBIO。BBIO 在 2027 年的整体展望偏积极，在覆盖分析师中约 92% 对应 Buy 共识。
常见问题
BBIO 预测 · 8 个问题根据 26 位华尔街分析师，BBIO 的 12 个月平均目标价为 $105.21，最高 $157.00、最低 $83.00。若有图表，中位目标价可在上方查看。相对当前价 $67.61，隐含约 +55.6% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.